Extrastriatal D2 and striatal D2 receptors in depressive illness: Pilot PET studies using [11C]FLB 457 and [11C]raclopride

Journal of Affective Disorders

Volumn 101, Issue 1-3, 2007, Pages 113-122

  Montgomery, Andrew J ^a   Stokes, Paul ^a   Kitamura, Yuri ^b   Grasby, Paul M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

11C raclopride; Antidepressant; Dopamine; PET; SSRI; 11C FLB 457

Indexed keywords

CITALOPRAM; DOPAMINE 2 RECEPTOR; ESCITALOPRAM; FLUOXETINE; ISOREMOXIPRIDE C 11; RACLOPRIDE C 11; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ISOREMOXIPRIDE; PYRROLIDINE DERIVATIVE; RACLOPRIDE; SALICYLAMIDE DERIVATIVE;

ADULT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG DISTRIBUTION; FEMALE; GENDER; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATE CORTEX; BRAIN; BRAIN MAPPING; CORPUS STRIATUM; IMAGE PROCESSING; MAJOR DEPRESSION; MIDDLE AGED; MOTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY; REFERENCE VALUE; SCINTISCANNING;

ADULT; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MOTIVATION; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; SALICYLAMIDES; SEROTONIN UPTAKE INHIBITORS;

EID: 34249951302     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2006.11.010     Document Type: Article

References (74)

1. Aalto S., Bruck A., Laine M., Nagren K., and Rinne J.O. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J. Neurosci. 25 (2005) 2471-2477
2. Ainsworth K., Smith S., Zetterstrom T., Pei Q., Franklin M., and Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) 140 (1998) 470-477
3. Ainsworth K., Smith S.E., and Sharp T. Repeated administration of fluoxetine, desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat. J. Psychopharmacol. 12 (1998) 252-257
4. Allard P., and Norlen M. Caudate nucleus dopamine D(2) receptors in depressed suicide victims. Neuropsychobiology 44 (2001) 70-73
5. Ashburner J., and Friston K. Non-linear spatial normalisation using basis functions. Hum. Brain Mapp. 7 (1999) 254-266
6. Asselin M.-C., Montgomery A., Hume S., Cunningham V.J., and Grasby P. Quantification of PET studies with the very high affinity D2/D3 receptor ligand [C-11]FLB-457: effects of co-injected stable FLB-457. Molec. Imaging Biol. 5 (2003) 98
7. Asselin, M.-C., Montgomery, A.J., Grasby, P.M., Hume, S.P., in press. Quantification of PET studies with the very high-affinity dopamine D(2)/D(3) receptor ligand [(11)C]FLB 457: re-evaluation of the validity of using a cerebellar reference region. J. Cereb. Blood Flow Metab. (Electronic publication ahead of print 2006 May 24).
8. Banki C.M. Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders. J. Neurochem. 28 (1977) 255-257
9. Barrett S.P., Boileau I., Okker J., Pihl R.O., and Dagher A. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54 (2004) 65-71
10. Battle G. A block spin construction of ondelettes:1. Lemarie functions. Commun. Math. Phys. 7 (1987) 601-615
11. Beskow J., Gottfries C.G., Roos B.E., and Winblad B. Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group. Acta Psychiatr. Scand. 53 (1976) 7-20
12. Bowden C., Cheetham S.C., Lowther S., Katona C.L., Crompton M.R., and Horton R.W. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 769 (1997) 135-140
13. Bowden C., Theodorou A., Cheetham S., Lowther S., Katona C., Crompton M., and Horton R. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 752 (1997) 227-233
14. Bowers Jr. M.B., Heninger G.R., and Gerbode F. Cerebrospinal fluid 5-hydroxyindoleactiic acid and homovanillic acid in psychiatric patients. Int. J. Neuropharmacol. 8 (1969) 255-262
15. Carson R.E., Breier A., de Bartolomeis A., Saunders R.C., Su T.P., Schmall B., Der M.G., Pickar D., and Eckelman W.C. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17 (1997) 437-447
16. Clark R.N., Ashby Jr. C.R., Dewey S.L., Ramachandran P.V., and Strecker R.E. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 23 (1996) 125-131
17. Crow T.J., Cross A.J., Cooper S.J., Deakin J.F., Ferrier I.N., Johnson J.A., Joseph M.H., Owen F., Poulter M., Lofthouse R., et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23 (1984) 1561-1569
18. Dagher A., Gunn R., Lockwood G., Cunningham V., Grasby P., and Brooks D. Measuring neurotransmitter release with PET: methodological issues. In: Carson R., Daube-Witherspoon M., and Herscovitch P. (Eds). Quantitative Functional Brain Imaging with Positron Emission Tomography (1998), Academic Press 449-454
19. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Fowler J.S., and Wolf A.P. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13 (1993) 350-356
20. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., and Ashby Jr. C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15 (1995) 821-829
21. D'haenen H., and Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission tomography. Biol. Psychiatry 35 (1994) 128-132
22. D'Haenen H., Bossuyt A., Mertens J., Bossuyt-Piron C., Gijsemans M., and Kaufman L. SPECT imaging of serotonin2 receptors in depression. Psychiatry Res. 45 (1992) 227-237
23. Drevets W., Price J., Kupfer D., Kinahan P., Lopresti B., Holt D., and Mathis C. PET measurement of amphetamine induced dopamine release in ventral and dorsal striatum. Neuropsychopharmacology 21 (1999) 694-709
24. Dziedzicka-Wasylewska M., Dlaboga D., Pierzchala-Koziec K., and Rogoz Z. Effect of tianeptine and fluoxetine on the levels of Met-enkephalin and mRNA encoding proenkephalin in the rat. J. Physiol. Pharmacol. 53 (2002) 117-125
25. Ebert D., Feistel H., Kaschka W., Barocka A., and Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol. Psychol. 35 (1994) 880-885
26. Ebert D., Feistel H., and Loew F. Dopamine and depression - striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126 (1996) 91-94
27. Edwards B.C., Lambert M.J., Moran P.W., McCully T., Smith K.C., and Ellingson A.G. A meta-analytic comparison of the Beck Depression Inventory and the Hamilton Rating Scale for Depression as measures of treatment outcome. Br. J. Clin. Psychol. 23 Pt 2 (1984) 93-99
28. Faravelli C., Albanesi G., and Poli E. Assessment of depression: a comparison of rating scales. J. Affect. Disord. 11 (1986) 245-253
29. Farde L., Pauli S., Hall H., Eriksson L., Halldin C., Hogberg T., Nilsson L., Sjogren I., and Stone-Elander S. Stereoselective binding of 11C-raclopride in living human brain-a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl) 94 (1988) 471-478
30. Hall H., Farde L., Halldin C., Hurd Y.L., Pauli S., and Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23 (1996) 115-123
31. Hamilton M.A. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
32. Hammers A., Koepp M.J., Free S.L., Brett M., Richardson M.P., Labbe C., Cunningham V.J., Brooks D.J., and Duncan J. Implementation and application of a brain template for multiple volumes of interest. Hum. Brain Mapp. 15 (2002) 165-174
33. Klimek V., Schenck J.E., Han H., Stockmeier C.A., and Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 52 (2002) 740-748
34. Klimke A., Larisch R., Janz A., Vosberg H., Muller-Gartner H., and Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 90 (1999) 91-101
35. Lammers C.H., Diaz J., Schwartz J.C., and Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry 5 (2000) 378-388
36. Larisch R., Klimke A., Vosberg H., Loffler S., Gaebel W., and Muller-Gartner H.W. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. NeuroImage 5 (1997) 251-260
37. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
38. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., and Innis R.B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17 (1997) 162-174
39. Leyton M., Boileau I., Benkelfat C., Diksic M., Baker G., and Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27 (2002) 1027-1035
40. Lucas G., and Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74 (2000) 693-701
41. Lucas G., De Deurwaerdere P., Porras G., and Spampinato U. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 39 (2000) 1984-1995
42. Lundkvist C., Sandell J., Nagren K., Pike V.W., and Halldin C. Improved synthesis of the PET radioligands, [11C]FLB 457, [11C]MDL 100907, [11C]B-CIT-FE, by the use of [11C]Methyl Triflate. J. Labelled Compd Radiopharm. XL1 (1998) 545-556
43. Luthra S., Osman S., Turton D., Vaja V., Dowsett K., and Brady F. An automated metabolite analysis system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [11C]L-deprenyl; [11C]diprenorphine, [11C]flumazenil, [11C]raclopride and [11C]SCH 23390. J. Labelled Compd Radiopharm. 32 (1993) 518-520
44. Maj J., Rogoz Z., Skuza G., and Sowinska H. Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist. J. Neural Transm.: Gen. Sect. 78 (1989) 1-8
45. Maj J., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., and Skuza G. Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur. J. Pharmacol. 304 (1996) 49-54
46. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., Cooper T., Kegeles L., Zarahn E., Abi-Dargham A., Haber S.N., and Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 23 (2003) 285-300
47. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., and Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21 (2001) 1034-1057
48. Meyer J.H., Gunn R.N., Myers R., and Grasby P.M. Assessment of spatial normalization of PET ligand images using ligand-specific templates. NeuroImage 9 (1999) 545-553
49. Montgomery A., McTavish S.F., Cowen P., and Grasby P. Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [11C]raclpride PET study. Am. J. Psychiatry 160 (2003) 1887-1889
50. Montgomery, A.J., Asselin, M.C., Farde, L., Grasby, P.M., in press. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J. Cereb. Blood Flow Metab. (Electronic publication ahead of print 2006 May 10).
51. Moses S.G., and Robins E. Regional distribution of norepinephrine and dopamine in brains of depressive suicides and alcoholic suicides. Psychopharmacol. Commun. 1 (1975) 327-337
52. Munro C.A., McCaul M.E., Wong D.F., Oswald L.M., Zhou Y., Brasic J., Kuwabara H., Kumar A., Alexander M., Ye W., and Wand G.S. Sex differences in striatal dopamine release in healthy adults. Biol. Psychiatry 59 (2005) 966-974
53. Ohmori T., Arora R.C., and Meltzer H.Y. Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol. Psychiatry 32 (1992) 57-71
54. Olsson H., Halldin C., Swahn C.G., and Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 19 (1999) 1164-1173
55. Olsson H., Halldin C., and Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage 22 (2004) 794-803
56. Pare C.M., Yeung D.P., Price K., and Stacey R.S. 5-hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet 2 (1969) 133-135
57. Parsey R.V., Oquendo M.A., Zea-Ponce Y., Rodenhiser J., Kegeles L.S., Pratap M., Cooper T.B., Van Heertum R., Mann J.J., and Laruelle M. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol. Psychiatry 50 (2001) 313-322
58. Penttila J., Kajander J., Aalto S., Hirvonen J., Nagren K., Ilonen T., Syvalahti E., and Hietala J. Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. Int. J. Neuropsychopharmacol. 7 (2004) 431-439
59. Pizzagalli D.A., Jahn A.L., and O'Shea J.P. Toward an objective characterization of an anhedonic phenotype: a signal-detection approach. Biol. Psychiatry 57 (2005) 319-327
60. Ranicar A.S., Williams C.W., Schnorr L., Clark J.C., Rhodes C.G., Bloomfield P.M., and Jones T. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med. Prog. Technol. 17 (1991) 259-264
61. Reddy P., Kanna S., and Sudash M. CSF amine metabolites in depression. Biol. Psychol. 31 (1992) 112-118
62. Schultz W., Tremblay L., and Hollerman J.R. Reward prediction in primate basal ganglia and frontal cortex. Neuropharmacology 37 (1998) 421-429
63. Shah P., Ogilvie A., Goodwin G., and Ebmeier K. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 27 (1997) 1247-1256
64. Small D.M., Jones-Gotman M., and Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. NeuroImage 19 (2003) 1709-1715
65. Spinks T.J., Jones T., Bloomfield P.M., Bailey D.L., Miller M., Hogg D., Jones W.F., Vaigneur K., Reed J., Young J., Newport D., Moyers C., Casey M.E., and Nutt R. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys. Med. Biol. 45 (2000) 2601-2618
66. Spyraki C., and Fibiger H.C. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur. J. Pharmacol. 74 (1981) 195-206
67. Studholme C., Hill D.L., and Hawkes D.J. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med. Phys. 24 (1997) 25-35
68. Tiihonen J., Kuoppamaki M., Nagren K., Bergman J., Eronen E., Syvalahti E., and Hietala J. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 126 (1996) 277-280
69. Turkheimer F.E., Brett M., Visvikis D., and Cunningham V.J. Multiresolution analysis of emission tomography images in the wavelet domain. J. Cereb. Blood Flow Metab. 19 (1999) 1189-1208
70. Watabe H., Endres C.J., Breier A., Schmall B., Eckelman W.C., and Carson R.E. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J. Nucl. Med. 41 (2000) 522-530
71. Watson C.C., Newport D., and Casey M.E. A single scatter simulation technique for scatter correction in 3D PET. In: Grangeat P., and Amans J.-L. (Eds). Three-Dimensional Image Reconstruction in Radiation and Nuclear Medicine (1996), Kluwer Academic Publishers, Dordrecht 255-268
72. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom F., and Kupfer D. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 921-931
73. Xu M., Luk W.K., Cutler P.D., and Digby W.M. Local threshold for segmented attenuation correction of PET imaging of the thorax. IEEE Trans. Nucl. Sci. 41 (1994) 1532-1537
74. Zald D.H., Boileau I., El-Dearedy W., Gunn R., McGlone F., Dichter G.S., and Dagher A. Dopamine transmission in the human striatum during monetary reward tasks. J. Neurosci. 24 (2004) 4105-4112